Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies

PRISM BioLab, Co. Ltd. a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® plus Yervoy® as a first-line treatment

Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss

Isotopia Molecular Imaging is proud to announce the official launch of Isoprotrace®, its advanced Gallium-68 Gozetotide

IDEAYA Biosciences, Inc. a precision medicine oncology company committed to the discovery and development of targeted therapeutics

PharmaLogic Holdings Corp. a leading contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals

AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced a new pipeline program in collaboration

GC Biopharma announced that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine

AbbVie today announced that the European Commission (EC) granted marketing authorization to RINVOQ® for the treatment of giant cell arteritis (GCA)